Immunotherapy plus chemo shows promise against tough stomach cancer
NCT ID NCT07257575
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard FLOT chemotherapy can improve outcomes for people with stage III gastric cancer. About 138 participants will receive either the combo or chemo alone before surgery. The main goal is to see if the combo leads to a higher rate of complete cancer disappearance in tissue samples after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Serplulimab (an immunotherapy drug) combined with FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel)
- What this could lead to
- If successful, this combination could increase the chance of eliminating all visible cancer before surgery, potentially improving long-term outcomes for patients with advanced gastric cancer.
- What could go wrong
- This is a mid-stage trial with only 138 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the added benefit over chemotherapy alone is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No. 106, Zhongshan 2nd Road, Yuexiu District
Guangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.